Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s shares gained 19.80% to $42.51. The company on Apr. 6 announced that data from its lead, first-in-class program AG-221 will be presented at a Clinical Trials Symposium titled “Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors” at the American Association for Cancer Research (AACR) Annual Meeting 2014. Agios Pharmaceuticals Inc (NASDAQ:AGIO)shares after opening at $43.25 moved to $46.00 on last trade day and at the end of the day closed at $45.35. Company price to sales ratio in past twelve months was calculated as 56.18 and price to cash ratio as 8.59. Agios Pharmaceuticals Inc (NASDAQ:AGIO) showed a positive weekly performance of 15.84%.
Sarepta Therapeutics (NASDAQ:SRPT) a developer of innovative RNA-based therapeutics, announced that it is scheduled to present at the 2014 Annual Needham Healthcare Conference in New York, NY on Tuesday, April 8, 2014 at 12:10 p.m. Eastern Time. Sarepta Therapeutics Inc (NASDAQ:SRPT) shares advanced 7.29% in last trading session and ended the day on $24.73. SRPT return on equity ratio is recorded as -66.80% and its return on assets is -46.00%. Sarepta Therapeutics Inc (NASDAQ:SRPT) yearly performance is -31.02%.
RadNet Inc. (NASDAQ:RDNT) issued a press release announcing the final results of its previously-announced tender offer and consent solicitation, commenced on March 7, 2014, for its 10 3/8% Senior Notes due 2018. RadNet Inc. (NASDAQ:RDNT) shares moved up 8.36% in last trading session and was closed at $3.76 while trading in range of $3.48 – $3.97 – RadNet Inc. (NASDAQ:RDNT) year to date (YTD) performance is 125.15%.
TheStreet Ratings team rates PIXELWORKS INC (NASDAQ:PXLW) as a Sell with a ratings score of D. Pixelworks, Inc. (NASDAQ:PXLW) weekly performance is -0.54%. On last trading day company shares ended up $5.51. Pixelworks, Inc. (NASDAQ:PXLW) distance from 50-day simple moving average (SMA50) is -0.58%. Analysts mean target price for the company is $10.00.